Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor

뉴스 본문을 불러오고 있어요.

Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor | 웨이프 WAPE

Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor

기사 요약

관련 종목

댓글 —